Success Metrics

Clinical Success Rate
90.0%

Based on 18 completed trials

Completion Rate
90%(18/20)
Active Trials
0(0%)
Results Posted
83%(15 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_4
6
27%
Ph not_applicable
2
9%
Ph phase_3
9
41%
Ph phase_2
4
18%

Phase Distribution

0

Early Stage

4

Mid Stage

15

Late Stage

Phase Distribution21 total trials
Phase 2Efficacy & side effects
4(19.0%)
Phase 3Large-scale testing
9(42.9%)
Phase 4Post-market surveillance
6(28.6%)
N/ANon-phased studies
2(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

18 of 21 finished

Non-Completion Rate

14.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Completed(18)
Terminated(3)
Other(1)

Detailed Status

Completed18
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (19.0%)
Phase 39 (42.9%)
Phase 46 (28.6%)
N/A2 (9.5%)

Trials by Status

completed1882%
unknown15%
terminated29%
withdrawn15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT01742832Phase 2

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Completed
NCT01878292Phase 3

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Completed
NCT01629966Phase 3

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

Completed
NCT01844115Phase 3

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Completed
NCT02372799Phase 3

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

Completed
NCT02436239Phase 3

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder

Completed
NCT01828515Phase 2

Vilazodone for Corticosteroid-Induced Memory Impairment

Completed
NCT01999920Phase 4

Vilazodone for Separation Anxiety Disorder

Completed
NCT00644358Phase 3

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Completed
NCT02028026Phase 4

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Withdrawn
NCT01856127Phase 4

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Terminated
NCT01574183Phase 2

Vilazodone Treatment for Marijuana Dependence

Completed
NCT01573598Phase 4

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Completed
NCT02015546Phase 3

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

Completed
NCT01680900Not Applicable

Vilazodone for Menopausal Hot Flashes

Completed
NCT01473381Phase 4

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Completed
NCT01473394Phase 4

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Completed
NCT01712321Not Applicable

Study of Vilazodone to Treat Social Anxiety Disorder

Unknown
NCT00290914Phase 2

Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22